var data={"title":"Calcium gluconate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcium gluconate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5793?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcium-gluconate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcium gluconate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=calcium-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcium gluconate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6026083\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cal-Glu [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144682\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Calcium Salt;</li>\n      <li>\n        Electrolyte Supplement, Oral;</li>\n      <li>\n        Electrolyte Supplement, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144662\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosages are expressed in terms of the <span style=\"text-decoration: underline\">calcium gluconate salt</span> (unless otherwise specified as elemental calcium). Dosages expressed in terms of the <span style=\"text-decoration: underline\">calcium gluconate salt</span> are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypocalcemia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild (ionized calcium: 4 to 5 mg/dL [1 to 1.2 mmol/L]): 1,000 to 2,000 mg over 2 hours; asymptomatic patients may be given oral calcium (Ariyan 2004; French 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe (without seizure or tetany; ionized calcium: &lt;4 mg/dL [&lt;1 mmol/L]): 4,000 mg over 4 hours (French 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe symptomatic (eg, seizure, tetany): 1,000 to 2,000 mg over 10 minutes; repeat every 60 minutes until symptoms resolve (French 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Repeat ionized calcium measurement 6 to 10 hours after completion of administration. Check for hypomagnesemia and correct if present. Consider continuous infusion if hypocalcemia is likely to recur due to ongoing losses (French 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 5 to 20 mg/kg/hour (Pai 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypocalcemia induced by citrate-based replacement fluid during continuous renal replacement therapy (CRRT) (off-label dose)</b>: IV (administered via return line): <b>Note:</b> Prior to initiation of CRRT, check ionized calcium and administer calcium gluconate if &lt;4 mg/dL (&lt;1 mmol/L) until &gt;4 mg/dL (&gt;1 mmol/L). During CRRT, a continuous infusion sliding scale may be initiated (may use calcium gluconate 20 gram/1,000 mL NS or D5W solution). The following schema has been employed (Palsson 1999):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ionized calcium is &lt;3.6 mg/dL (&lt;0.9 mmol/L): Notify nephrology.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ionized calcium is 3.6 to 4 mg/dL (0.9 to 1 mmol/L): 1,400 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ionized calcium is 4 to 4.4 mg/dL (1 to 1.1 mmol/L): 1,200 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ionized calcium is 4.4 to 5.2 mg/dL (1.1 to 1.3 mmol/L): 1,000 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ionized calcium is &gt;5.2 mg/dL (&gt;1.3 mmol/L): Notify nephrology.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:</b> IV: 1,500 to 3,000 mg over 2 to 5 minutes (Vanden Hoek 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (Neumar 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Parenteral nutrition, maintenance requirement:</b> IV: <b>Note:</b> Expressed in terms of <b>elemental calcium:</b> 10 to 20 <b>mEq elemental calcium</b> daily (ASPEN [Mirtallo 2004]). Adjust dose based on total or ionized calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Calcium channel blocker overdose (off-label use):</b> <i>Hypotension/conduction disturbances:</i> IV: 60 mg/kg/dose over 5 to 10 minutes (maximum: 3,000 to 6,000 mg/dose); may repeat every 10 to 20 minutes for 3 to 4 additional doses (AHA [Vanden Hoek 2010]; DeWitt 2004) <b>or</b> initiate a continuous infusion of 60 to 150 mg/kg/<b>hour</b> titrated to improve blood pressure and contractility (DeWitt 2004; Kerns 2007; Salhanick 2003). Maintain ionized calcium at a goal of twice normal (Kerns 2007). In life-threatening situations, 1,000 mg has been administered every 2 to 3 minutes until clinical effect is achieved (Buckley 1994). In one report, 18 <b>g</b> was administered over a 3-hour period (Luscher 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Beta-blocker overdose (off-label use):</b> <i>Hypotension/conduction disturbances: </i>IV: 60 mg/kg over 5 to 10 minutes followed by an infusion of 60 to 150 mg/kg/hour; titrate to adequate hemodynamic response (AHA [Vanden Hoek 2010]; Kerns 2007).<b> Note:</b> Optimal dose has not been established (DeWitt 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hydrofluoric acid burns, treatment (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ (off-label): 5% to 10% solution: 0.5 <b>mL</b>/cm<sup>2</sup> of burned tissue (Dibbell 1970; Hatzifotis 2004; Kirkpatrick 1995; Krenzelok 1999). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy (<b>Note: Never</b> use calcium chloride for subcutaneous injection).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intra-arterial (off-label): Add 10 <b>mL</b> of a 10% solution to 50 mL of D5W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (Hatzifotis 2004; Kirkpatrick 1995). Pain usually resolves by the end of the infusion; repeat if pain recurs. <b>This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation (off-label): 2.5% nebulization solution: Mix 1.5 <b>mL</b> of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (Upfal 1990).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144675\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=calcium-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcium gluconate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosages are expressed in terms of the <span style=\"text-decoration: underline\">calcium gluconate salt</span> (unless otherwise specified as elemental calcium). Dosages expressed in terms of the <span style=\"text-decoration: underline\">calcium gluconate salt</span> are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg)/mL elemental calcium, except where noted.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypocalcemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">General dosing: Infants, Children, and Adolescents: IV: 200 to 500 mg/kg/day as a continuous infusion or in 4 divided doses (maximum dose: 1,000 mg/dose [Infants, Children]; 2,000 to 3,000 mg/dose [Adolescents]) (Edmondson 1990; Zhou 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic (ie, seizures, tetany): Infants, Children, and Adolescents: IV: 100 to 200 mg/kg/dose over 5 to 10 minutes; usual adult dose: 1,000 to 2,000 mg/dose; may repeat after 6 hours or follow with a continuous infusion of 200 to 800 mg/kg/day (Edmondson 1990; Kelly 2013; Misra 2008; Nelson 1996; Zhou 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cardiac arrest or cardiotoxicity in the presence of hyperkalemia, hypocalcemia, or hypermagnesemia:</b> Infants, Children, and Adolescents: IV, intraosseous: 60 to 100 mg/kg/dose (maximum: 3,000 mg/dose); may repeat in 10 minutes if necessary; if effective, consider IV infusion (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (Kleinman 2010; Neumar 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Parenteral nutrition, maintenance requirement:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children (&le;50 kg) (Mirtallo 2004): <b>Note:</b> Dose expressed as <b>elemental calcium:</b> 0.5 to 4 <b>mEq elemental calcium</b>/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children (&gt;50 kg) and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Calcium channel blocker overdose (off-label use):</b> <i>Hypotension/conduction disturbances:</i> Infants, Children, and Adolescents: IV, intraosseous: 60 mg/kg/dose administered over 30 to 60 minutes (Hegenbarth 2008). <b>Note:</b> Calcium chloride may provide a more rapid increase of ionized calcium in critically-ill children. Calcium gluconate may be substituted if calcium chloride is not available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hydrofluoric acid burns, treatment (off-label use):</b> Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144663\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144664\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Initiate with the lower limit of the dosage range (accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14791789\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. In patients in the anhepatic stage of liver transplantation, equal rapid increases in ionized concentrations occur suggesting that calcium gluconate does not require hepatic metabolism for release of ionized calcium (Martin 1990).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144645\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cal-Glu: 500 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (10 mL, 50 mL, 100 mL); 1% in Dextrose 5% (100 mL); 1% in NaCl 0.9% (100 mL); 2% in Dextrose 5% (50 mL, 100 mL); 2% in NaCl 0.9% (50 mL, 100 mL); 3% in NaCl 0.9% (100 mL); 4% in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (10 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144630\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21879420\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">1 g calcium gluconate = elemental calcium 93 mg = calcium 4.65 mEq = calcium 2.33 mmol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144649\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with plenty of fluids with or following meals. The 10% calcium gluconate injection may be administered orally in young pediatric patients (Mimouni 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV: For bolus or continuous infusion. Administer bolus slowly (not to exceed 200 mg/minute in adults or 100 mg/minute in pediatric patients). For continuous infusions, adjust rate as needed based on serum calcium levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Due to the potential presence of particulates, American Regent, Inc recommends the use of a 0.22 micron inline filter for IV administration (1.2 micron filter if admixture contains lipids) (Important Drug Administration Information, American Regent 2013); a similar recommendation has not been noted by other manufacturers. Not for IM administration. In acute situations of symptomatic hypocalcemia, infusions over 5 to 10 minutes have been described in pediatric patients (Kelly 2013; Misra 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Early/acute calcium extravasation</i>: Initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses; elevate extremity (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hyaluronidase: Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981). May also inject hyaluronidase through the catheter that caused the infiltration (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Delayed calcium extravasation:</i> Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sodium thiosulfate: IV: 12.5 g over 30 minutes; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Treatment of hydrofluoric acid burns (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>SubQ infiltration (off-label route):</i> Using a 27- or 30-gauge needle, approach the wound from the distal point of injury and infiltrate directly into the affected dermis and subcutaneous tissue. The infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas (Dibbell 1970). Avoid excessive administration as it can cause compartment syndrome and further exacerbate tissue damage. Following subungual exposure, administer to the affected area via the lateral or volar route through the fat pad (under digital nerve block); administration may also require removal of the nailbed, splitting the distal nail from the nailbed, or trimming the nail to the nailbed to reach the affected area (Kirkpatrick 1995; Roberts 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intra-arterial (off-label route):</i> Requires radiology to place an arterial catheter in an artery supplying blood to the area of exposure; infuse over four hours (Vance 1986). <b>This intervention should be used only by those accustomed to this technique. Care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation:</i> Dilute 10% calcium gluconate solution to a 2.5% solution and administer via nebulization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144648\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary supplement (oral only):</b> Dietary calcium supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia (IV only):</b> Treatment of acute symptomatic hypocalcemia in adult and pediatric patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475298\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Beta-blocker overdose (shock refractory to other measures); Calcium channel blocker overdose; Hydrofluoric acid burn</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144690\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcium gluconate may be confused with calcium glubionate, cupric sulfate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Calcium gluconate may be confused with calcium chloride.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between calcium gluconate (in which 1 g = 4.65 mEq [90 mg] of elemental Ca++) and calcium chloride (in which 1 g = 14 mEq [270 mg] of elemental Ca++).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prescribers should specify which salt form is desired. Dosages should be expressed either as mEq, mg, or grams of the salt form.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144637\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, decreased blood pressure, syncope, vasodilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, feeling hot</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Unusual taste (chalky)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tingling sensation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144652\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypercalcemia; concomitant use of IV calcium gluconate with ceftriaxone in neonates (&le;28 days of age).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144634\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Parenteral calcium is a vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the IV site closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Constipation, bloating, and gas are common with oral calcium supplements (especially carbonate salt).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Avoid too-rapid IV administration (do not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients); may result in vasodilation, hypotension, bradycardia, arrhythmias, syncope, and cardiac arrest. Safety for long-term use has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral administration: Administering oral calcium with food and vitamin D will optimize calcium absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in susceptible individuals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298941\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144639\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9190&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a caclium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any calcium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estramustine: Calcium Salts may decrease the absorption of Estramustine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. <b> Exceptions: </b>LevoFLOXacin (Oral Inhalation); Moxifloxacin (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1891176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1891178\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Calcium is present in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50961845\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dietary reference intake for calcium (IOM 2011):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to &lt;6 months: Adequate intake: 200 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 to 12 months: Adequate intake: 260 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: RDA: 700 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 8 years: RDA: 1,000 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 18 years: RDA: 1,300 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 50 years: RDA: 1,000 mg <b>elemental calcium </b>daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: &ge;51 years: RDA: 1,200 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: 51 to 70 years: RDA: 1,000 mg <b>elemental calcium</b> daily; &gt;70 years: RDA: 1,200 mg <b>elemental calcium</b> daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49335503\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Serum calcium every 4 hours (during intermittent infusion) or every 1 to 4 hours (during continuous infusion); albumin, phosphate, and magnesium; vitals and ECG when appropriate. Monitor infusion site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Calcium channel blocker overdose, beta-blocker overdose (off-label uses):</i> Monitor hemodynamic response; monitor serum ionized calcium levels every 30 minutes initially, then every 2 hours and maintain ionized calcium ~2 times the ULN; avoid severe hypercalcemia (ionized calcium levels &gt;2 times ULN) (Kerns 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144646\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum total calcium: 8.4 to 10.2 mg/dL (2.1 to 2.55 mmol/L). <b>Note:</b> Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum ionized calcium: 4.48 to 5.32 mg/dL (1.12 to 1.33 mmol/L) (Zaloga 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In low albumin states, the corrected <b>total</b> serum calcium may be estimated by the following equation (assuming a normal albumin of 4 g/dL [40 g/L]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total calcium (mg/dL) = measured total calcium (mg/mL) + 0.8 [4-measured serum albumin (g/dL)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total calcium (mmol/L) = measured total calcium (mmol/L) + 0.02 [40-measured serum albumin (g/L)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144633\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderates nerve and muscle performance via action potential threshold regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In hydrogen fluoride exposures, calcium gluconate provides a source of calcium ions to complex free fluoride ions and prevent or reduce toxicity; administration also helps to correct fluoride-induced hypocalcemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144651\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Minimal unless chronic, high doses are given; predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acidic environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Primarily in skeleton (99%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~40%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily feces (75%; as unabsorbed calcium salts); urine (20%) (IOM 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323034\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (100 mL): $36.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/50 mL 5% (50 mL): $14.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $14.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 5% (100 mL): $23.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/250ML 5% (250 mL): $41.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcium Gluconate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 0.9% (100 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/50ML 0.9% (50 mL): $13.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 0.9% (100 mL): $22.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $25.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3GM/100ML 0.9% (100 mL): $33.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Calcium Gluconate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $23.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Calcium Gluconate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $16.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038547\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biogam Ca (BE);</li>\n      <li>Calcedon (DE);</li>\n      <li>Calcii Gluconas (FI);</li>\n      <li>Calcimusc (HU);</li>\n      <li>Calcinate (PH);</li>\n      <li>Calcio Gluconato (AR, IT);</li>\n      <li>Calcium Braun (DE);</li>\n      <li>Calcium Gluconate (AU);</li>\n      <li>Calcium Gluconicum (BG, PL);</li>\n      <li>Calcium Gluconicum Granulatum (PL);</li>\n      <li>Calcium Pliva (PL);</li>\n      <li>Calcium Polfa (PL);</li>\n      <li>Folinex 50 (LK);</li>\n      <li>Glucal (ZA);</li>\n      <li>Gluconate de Calcium Lavoisier (FR);</li>\n      <li>Novacalc (NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &quot;2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities,&rdquo; <i>Circulation</i>, 2005, 112:IV121&ndash;5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariyan CE and Sosa JA, &ldquo;Assessment and Management of Patients With Abnormal Calcium,&rdquo; <i>Crit Care Med</i>, 2004, 32(4 Suppl):146-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/15064673/pubmed\" target=\"_blank\" id=\"15064673\">15064673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bentur Y, Biran I, and Miller B, &ldquo;Evaluation of the Efficacy of 1% Calcium Gluconate in the Treatment of Hydrofluoric Acid (HF) Eye Burn,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):535.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckley NA, Whyte IM, and Dawson AH, &ldquo;Overdose With Calcium Channel Blockers,&rdquo; <i>BMJ</i>, 1994, 308(6944):1639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/8025446/pubmed\" target=\"_blank\" id=\"8025446\">8025446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcium gluconate injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeRoos F, &ldquo;Calcium Channel Blockers,&rdquo; Goldfrank LG, et al, ed,<i>Goldfrank&rsquo;s Toxicologic Emergencies</i>, 7th ed, New York, (NY):McGraw-Hill Medical Publishing, 2002, 762-74.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeWitt CR and Walsman JC, &ldquo;Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity,&rdquo; <i>Toxicol Rev</i>, 2004, 23(4):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/15898828/pubmed\" target=\"_blank\" id=\"15898828\">15898828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"5479482\"></a>Dibbell DG, Iverson RE, Jones W, et al, &quot;Hydrofluoric Acid Burns of the Hand,&quot; <i>J Bone Joint Surg Am</i>, 1970, 52(5):931-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/5479482/pubmed\" target=\"_blank\" id=\"5479482\">5479482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edmondson S, Almquist TD. Iatrogenic hypocalcemic tetany. <i>Ann Emerg Med</i>. 1990;19(8):938-940.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/2372181/pubmed\" target=\"_blank\" id=\"2372181\">2372181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French S, Subauste J, and Geraci S, &ldquo;Calcium Abnormalities in Hospitalized Patients,&rdquo; <i>Southern Med J</i>, 2012, 105(4):231-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/22475676/pubmed\" target=\"_blank\" id=\"22475676\">22475676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15019125\"></a>Hatzifotis M, Williams A, Muller M, et al, &quot;Hydrofluoric Acid Burns,&quot; <i>Burns</i>, 2004, 30(2):156-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/15019125/pubmed\" target=\"_blank\" id=\"15019125\">15019125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heaney RP, Recker RR, and Saville PD, &ldquo;Menopausal Changes in Calcium Balance Performance,&rdquo; <i>J Lab Clin Med</i>, 1978, 92(6):953-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/739173/pubmed\" target=\"_blank\" id=\"739173\">739173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18245435\"></a>Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howarth DM, Dawson AH, Smith AJ, et al, &ldquo;Calcium Channel Blocking Drug Overdose: An Australian Series,&rdquo; <i>Hum Exp Toxicol</i>, 1994, 13(3):161-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/7909677/pubmed\" target=\"_blank\" id=\"7909677\">7909677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Important drug administration information: calcium gluconate injection, USP 10% [written communication]. Shirley, NY: American Regent Inc; March 18, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D</i>, Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isbister GK, &ldquo;Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose,&rdquo; <i>Emerg Med J</i>, 2002, 19(4):355-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/12101159/pubmed\" target=\"_blank\" id=\"12101159\">12101159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly A, Levine MA. Hypocalcemia in the critically ill patient. <i>J Intensive Care Med</i>. 2013;28(3):166-177. 10.1177/0885066611411543.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/21841146/pubmed\" target=\"_blank\" id=\"21841146\">21841146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. <i>Emerg Med Clin North Am</i>. 2007;25(2):309-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/17482022/pubmed\" target=\"_blank\" id=\"17482022\">17482022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8540974\"></a>Kirkpatrick JJ and Burd DAR, &ldquo;An Algorithmic Approach to the Treatment of Hydrofluoric Acid Burns,&rdquo; <i>Burns</i>, 1995, 21(7):495-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/8540974/pubmed\" target=\"_blank\" id=\"8540974\">8540974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Krenzelok.1999\"></a>Krenzelok EP, &quot;Hydrofluoric Acid Exposures,&quot; <i>Clinical Environmental Health and Toxic Exposures</i>, 2nd ed, Sullivan JB and Krieger GR, eds, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 1999, 798-806.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam YM, Tse HF, and Lau CP, &ldquo;Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium,&rdquo; <i>Chest</i>, 2001, 119(4):1280-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/11296202/pubmed\" target=\"_blank\" id=\"11296202\">11296202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8669723\"></a>Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. <i>Ann Emerg Med</i>. 1996;28(1):1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/8669723/pubmed\" target=\"_blank\" id=\"8669723\">8669723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luscher TF, Noll G, and Sturmer T, &ldquo;Calcium Gluconate in Severe Verapamil Intoxication,&rdquo; <i>N Engl J Med</i>, 1994, 330(10):718-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/8107735/pubmed\" target=\"_blank\" id=\"8107735\">8107735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin TJ, Kang Y, Robertson KM, et al, &ldquo;Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function,&rdquo; <i>Anesthesiology</i>, 1990, 73(1):62-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/2360741/pubmed\" target=\"_blank\" id=\"2360741\">2360741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Millard TP, Harris AJ, and MacDonald DM, &quot;Calcinosis Cutis Following Intravenous Infusion of Calcium Gluconate,&quot; <i>Br J Dermatol</i>, 1999, Jan;140(1):184-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/10215803/pubmed\" target=\"_blank\" id=\"10215803\">10215803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mimouni F, Tsang RC. Neonatal hypocalcemia: to treat or not to treat? (A review). <i>J Am Coll Nutr</i>. 1994;13(5):408-415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/7836618/pubmed\" target=\"_blank\" id=\"7836618\">7836618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &quot;Safe Practices for Parenteral Nutrition,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. <i>Pediatrics</i>. 2008;122(2):398-417. doi: 10.1542/peds.2007-1894.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/18676559/pubmed\" target=\"_blank\" id=\"18676559\">18676559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, Arvin AM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WR Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai AB, &ldquo;Chapter 59: Disorders of Calcium and Phosphorus Homeostasis,&rdquo; <i>Pharmacotherapy: A Pathophysiologic Approach</i>, 8th ed, Talbert RL, DiPiro JT, Matzke GR, et al, eds, New York, NY:McGraw-Hill, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. <i>Kidney Int</i>. 1999;55(5):1991-1997.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/10231464/pubmed\" target=\"_blank\" id=\"10231464\">10231464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearigen PD and Benowitz NL, &ldquo;Poisoning Due to Calcium Antagonists: Experience With Verapamil, Diltiazem, and Nifedipine,&rdquo; <i>Drug Saf</i>, 1991, 6(6):408-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/1793522/pubmed\" target=\"_blank\" id=\"1793522\">1793522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"709264\"></a>Perkins CM. Serious verapamil poisoning: treatment with intravenous calcium gluconate. <i>Br Med J</i>. 1978;2(6145):1127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/709264/pubmed\" target=\"_blank\" id=\"709264\">709264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9624322\"></a>Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. <i>Ann Emerg Med</i>. 1998;31(6):777-781.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/9624322/pubmed\" target=\"_blank\" id=\"9624322\">9624322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8427431\"></a>Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. <i>Ann Emerg Med</i>. 1993;22(2):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/8427431/pubmed\" target=\"_blank\" id=\"8427431\">8427431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Recker RR, &ldquo;Calcium Absorption and Achlorhydria,&rdquo; <i>N Engl J Med</i>, 1985, 313(2):70-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/4000241/pubmed\" target=\"_blank\" id=\"4000241\">4000241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts JR and Merigian KS, &quot;Acute Hydrofluoric Acid Exposure,&quot; <i>Am J Emerg Med</i>, 1989, 7(1):125-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/2914038/pubmed\" target=\"_blank\" id=\"2914038\">2914038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salhanick SD and Shannon MW, &ldquo;Management of Calcium Channel Antagonist Overdose,&rdquo; <i>Drug Saf</i>, 2003, 26(2):65-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/12534324/pubmed\" target=\"_blank\" id=\"12534324\">12534324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt MJ and Bryant SM, &quot;Hydrofluoric Acid Burn to Penis,&quot; <i>Clin Toxicol (Phila)</i>, 2007, 45(6):732.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/17849253/pubmed\" target=\"_blank\" id=\"17849253\">17849253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trujillo M, Guerrero J, Fragachan C, et al, &quot;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration, <i>Crit Care Med</i>, 1998, 26(2):377-91.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Upfal M, Doyle C. Medical management of hydrofluoric acid exposure. <i>J Occup Med</i>. 1990;32(8):726-731.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/2401930/pubmed\" target=\"_blank\" id=\"2401930\">2401930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vance MV, Curry SC, Kunkel DB, et al, &ldquo;Digital Hydrofluoric Acid Burns: Treatment With Intraarterial Calcium Infusion,&rdquo; <i>Ann Emerg Med</i>, 1986, 15(8):890-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/3740574/pubmed\" target=\"_blank\" id=\"3740574\">3740574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Worthley LI and Phillips PJ, &ldquo;Intravenous Calcium Salts,&rdquo; <i>Lancet</i>, 1980, 2(8186):149.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaloga GP. Hypocalcemia in critically ill patients. <i>Crit Care Med</i>. 1992;20(2):251-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/1737459/pubmed\" target=\"_blank\" id=\"1737459\">1737459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhou P, Markowitz M. Hypocalcemia in infants and children. <i>Pediatr Rev</i>. 2009;30(5):190-192. doi: 10.1542/pir.30-5-190<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-gluconate-drug-information/abstract-text/19411338/pubmed\" target=\"_blank\" id=\"19411338\">19411338</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9190 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6026083\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F144682\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F144662\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F144675\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F144663\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F144664\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14791789\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F144645\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F144630\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21879420\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F144649\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F144648\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475298\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F144690\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144637\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F144652\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F144634\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298941\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F144639\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1891176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F1891178\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F50961845\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49335503\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F144646\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F144633\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F144651\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323034\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038547\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9190|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcium-gluconate-patient-drug-information\" class=\"drug drug_patient\">Calcium gluconate: Patient drug information</a></li><li><a href=\"topic.htm?path=calcium-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcium gluconate: Pediatric drug information</a></li></ul></div></div>","javascript":null}